However, traditional CAR T cell therapy has had limited success in solid tumors. Shipra Das, an immunooncologist at Cellectis, discussed a novel approach using transcription activation-like effector ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果